GC Therapeutics raises $75 million to transform cell therapy
Longevity Technology - 23-Sep-2024The startup leverages its TFome™ platform for rapid and efficient iPSC programming
Join the club for FREE to access the whole archive and other member benefits.
Research institute focused on developing bioinspired materials and devices
We employ a unique model of technology translation within academia. Technologies conceived in our research laboratories are refined and de-risked technically and commercially by our Advanced Technology and Business Development teams. Our technologies are licensed to newly-founded startup companies or industry partners to bring about positive, near-term impact in the world.
We aim to have near-term impact in the world by developing groundbreaking bioinspired technologies, ranging from novel devices and materials to high-value therapeutics and diagnostics, that are translated into commercial products and solutions.
Visit website: https://wyss.harvard.edu/
Details last updated 16-Sep-2019
The startup leverages its TFome™ platform for rapid and efficient iPSC programming
Engineers create lifelike vascular networks in heart tissue for future organ transplants
Bioelectric signals could even promote tissue regeneration
Japanese origami inspired robot perform precise and less invasive surgical tasks
Body-on-Chips platform is created by connecting 10 organ-chips to mimic normal human blood flow
DNA nanobots will soon be tried in a critically ill leukemia patient
Founding Director of the Wyss Institute for Biologically Inspired Engineering at Harvard University
CEO at Verve, Inc., and former Staff Engineer and Program Manager for Soft Wearable Robotic programs at the Wyss Institute.
Associate Professor in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School.
Biologist, population geneticist, mathematical modeler and Associate Professor at Harvard Medical School.